John Goldberg
Chief Tech/Sci/R&D Officer bei RAFAEL HOLDINGS, INC.
Vermögen: 344 $ am 31.12.2023
Profil
John M.
Goldberg is currently the Chief Medical Officer at Rafael Holdings, Inc. Prior to this, he was the Chief Medical Officer at Oncorus, Inc. from 2018 to 2023.
He also held the position of Senior Director-Medical at H3 Biomedicine, Inc. and Head-Clinical Development at Agenus, Inc. Dr. Goldberg received his undergraduate degree from The University of Chicago and his doctorate from the University of Massachusetts Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ONCORUS, INC.
0,01% | 31.03.2023 | 2 730 ( 0,01% ) | 344 $ | 31.12.2023 |
Aktive Positionen von John Goldberg
| Unternehmen | Position | Beginn |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 20.11.2023 |
Ehemalige bekannte Positionen von John Goldberg
| Unternehmen | Position | Ende |
|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 30.06.2023 |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Ausbildung von John Goldberg
| The University of Chicago | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Private Unternehmen | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
